Vaccines

Details Vaccines Vaccines

2008-07-15

2008-07-15

Campbell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S278100, C424S238100, C514S025000

Reexamination Certificate

active

07399472

ABSTRACT:
The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.

REFERENCES:
patent: 5057540 (1991-10-01), Kensil et al.
patent: 6231859 (2001-05-01), Kensil et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6544518 (2003-04-01), Friede et al.
patent: 6589940 (2003-07-01), Raz et al.
patent: 0 109 942 (1991-03-01), None
patent: 0 468 520 (1991-07-01), None
patent: 0 362 279 (1995-01-01), None
patent: 0 671 948 (1997-08-01), None
patent: 0 689 454 (1997-09-01), None
patent: 0 855 184 (1998-07-01), None
patent: 2 122 204 (1984-01-01), None
patent: WO95/17210 (1995-06-01), None
patent: WO96/02555 (1996-02-01), None
patent: WO96/11711 (1996-04-01), None
patent: 96/26741 (1996-09-01), None
patent: WO96/33739 (1996-10-01), None
patent: 96/40290 (1996-12-01), None
patent: WO98/15287 (1998-04-01), None
patent: WO98/16247 (1998-04-01), None
patent: WO98/18810 (1998-05-01), None
patent: WO98/20734 (1998-05-01), None
patent: WO98/28037 (1998-07-01), None
patent: WO98/37919 (1998-09-01), None
patent: WO98/40100 (1998-09-01), None
patent: WO98/55495 (1998-12-01), None
patent: WO98/55609 (1998-12-01), None
patent: WO98/56414 (1998-12-01), None
patent: WO98/56415 (1998-12-01), None
patent: WO99/10008 (1999-03-01), None
patent: WO99/12565 (1999-03-01), None
patent: WO99/33488 (1999-07-01), None
patent: WO99/61056 (1999-12-01), None
patent: WO99/62923 (1999-12-01), None
patent: WO 00/09159 (2000-02-01), None
patent: WO 01/51083 (2001-01-01), None
patent: WO 01/95935 (2001-01-01), None
Mowat et al., “Immune-stimulating complexes containing Quil A and protein antigen prime class etc.”,Immunology, 72, pp. 317-322 (1991).
Kensil et al., “Synergistic Action of QS-21 and CpG Adjuvants”,X5 DNA Vaccines, Abstract No. 218, (1999).
O. Gisvold, “Digitonin and Phytosterol From the See of Digitalis Purpurea”,Phytochemical Notes, 23(7), pp. 664-665 (1933).
Yoshikawa et al., “Bioactive Saponins and Glycosides, III. Horse Chestnut (1): etc.”,Chem. Pharm. Bull., 44(8), pp. 1454-1463 (1996).
Estrada et al., “Adjuvant action of Chenopodium quinoa saponins on the induction etc.”,Com. Immun. Microbiol.&Infect Dis., 21, pp. 225-236 (1998).
Kensil, “Saponins as Vaccine Adjuvants”,Critical Reviews in Therapeutic Drug Carrier Systems, 13(1&2), pp. 1-55 (1996).
Lacaille-Dubois et al., “A review of the biological and pharmacological activities of saponins”,Phytomedicine, 2(4), pp. 363-386 (1996).
Gizurarson et al., “Pharmaceutical Excipients and Absorption Promoters as Immunostimulants etc.”,Vaccine Research, 3(1), pp. 23-29 (1994).
Bumford et al., “Adjuvanticity and ISCOM formation by structurally diverse saponis”,Vaccine, 10(9), pp. 572-577 (1992).
Krieg et al., “CpG motifs in bacterial DNA trigger direct B-cell activation”,Nature, 374, pp. 546-549 (1995).
Kensil et al., “Separation and Characterization of Saponis with adjuvant Activity etc.”,Journal of Immunology, 146(2), pp. 431-437 (1991).
Chavali et al., “Adjuvant Effects of Orally Administered Saponis in Humoral etc.”,Immunobiol., 174, pp. 347-359 (1987).
Sasaki et al., “Induction of Systemic and Mucosal Immune Responses to Human etc.”,Journal of Virology, 72(6) pp. 4931-4939 (1998).
Maharaj et al., “Immune responses of mice to inactivated rabies vaccine etc.”,Can. J. Microbiol., 32, pp. 414-420 (1986).
Mowat et al., “ISCOMS-a novel strategy for mucosal immunization?”, Immunology Today, 12(11), pp. 383-385 (1991).
Brazolot-Millan et al., “CpG DNA can induce strong Th1 humoral and cell-mediated immune etc.”,Proc. Natl. Acad. Sci. USA, 95, pp. 15553-15558 (1988).
McCluskie et al., “Cutting Edge:CpG DNA is a potent enhancer of systemic and mucosal etc.”,J. Immunol., 161(9), pp. 4463-4466 (1998).
Davis et al., “CpG DNA is a patent enhancer of specific immunity in mice etc.”,J. Immunol., 160(2), pp. 870-876 (1998).
Dennis M. Klinman, “Therapeutic Applications of CpG-Containing Oligodeoxynucleotides”,Antisense&Nucleic Acid Drug Development, 8: 181-184 (1998).
Liu, et al., “Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor”,Blood, 92(10): 3730-3736 (1998).
Krieg, et al., The Role of CpG Dinucleotides in DNA VaccinesTrends in Microbiology, 6(1): 23-27 (1998).
So, et al., “Effect of a Novel Saponin Adjuvant Derived fromQuillaja saponariaon the Immune Response to Recombinant Hepititas B Surface Antigen”,Mol. Cells, 7(2): 178-186 (1997).
Lipford, et al., “CpG-Containing Synthetic Oligonucleotides Promote B and Cytotoxic T Cell Responses to Protein Antigen: A New Class of Vaccine Adjuvants”,Eur. J. Immunology, 27: 2340-2344 (1997).
Moldoveanu, et al., “CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization with Influenza Virus”,Vaccine, 16: 1216-1224 (1998).
Klinman, et al., “CpG Motifs as Immune Adjuvants”,Vaccine, 17: 19-25, (1999).
Barr, “ISCOMs and Other Saponin Based Adjuvants,”Advanced Drug Delivery Reviews, 1998 32:247-271.
Sjolander, “Uptake and Adjuvant Activity of Orally Delivered Saponin and ISCOM Vaccines,”Advanced Drug Delivery Reviews, 1998 34:321-338.
Takahashi, Induction of CD8+cytotoxic T Cells by Immunization with Purified HIV-1 envelope protein in ISCOMNature1990, 344:873-875.
Woolridge et al., Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma,Blood89(8):2994-2998 (Apr. 15, 1997).
Yi et al., CpG Motifs in Bacterial DAN Activate Leukocytes Through the pH-Dependent Generation of Reactive Oxygen Species,Journal of Immunology16:4755-4761 (1998).
Manmohan Singh 7 Derek O'Hagan, Ádvances in Vaccine Adjuvants, Nov. 1999, (pp. 1075-1081).

Affiliated with

Also associated with

Rating

Vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2760644